Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06125743 · ClinicalTrials.gov registry record · NA
Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]
A NA study of Lymphedema of the Head and Neck, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 204
- Enrollment target
- 2
- Study locations
NCT06125743: Recruiting NA study of Lymphedema of the Head and Neck, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06125743 is a NA study of Lymphedema of the Head and Neck that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 204 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06125743, a NA study of Lymphedema of the Head and Neck, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 204 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to evaluate the effectiveness of a standardized lymphedema and fibrosis self-management program (LEF-SMP) to improve LEF self-management and reduce LEF-associated symptom burden, functional deficits, and improve quality of life in head and neck cancer (HNC) survivors.
Primary Outcome
This outcome measure will be assessed via Head and Neck - External Lymphedema and Fibrosis Assessment Criteria (HN-LEF Assessment Criteria). The total severity score of lymphedema and fibrosis (LEF) is calculated by summing the severity score (normal = 0, mild =1, moderate =2, and severe =3) of each anatomical site affected by head and neck LEF. Higher scores mean a worse outcome.
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL In-Person LEF-SMP
- BEHAVIORAL Telehealth LEF-SMP
Study Locations (2)
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Barbara Murphy - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT06125743 shows while recruiting
NCT06125743 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Lymphedema of the Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Usual Care is the first listed.
NCT06125743 reports a single indexed study location in Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06125743 about?
NCT06125743 is a clinical study titled "Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]". The goal of this study is to evaluate the effectiveness of a standardized lymphedema and fibrosis self-management program (LEF-SMP) to improve LEF self-management and reduce LEF-associated symptom burden, functional deficits, and improve quality of life in head and neck cancer (HNC) survivors.
What is the current status of trial NCT06125743?
This trial is currently recruiting. It is a NA study. The enrollment target is 204 participants. The study started on 2024-03-29. Estimated completion is 2026-08-31.
What conditions does trial NCT06125743 study?
This clinical trial studies the following conditions: Lymphedema of the Head and Neck.
What interventions are being tested in trial NCT06125743?
The interventions under investigation include: Usual Care (BEHAVIORAL), In-Person LEF-SMP (BEHAVIORAL), Telehealth LEF-SMP (BEHAVIORAL).
Who is sponsoring clinical trial NCT06125743?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06125743 being conducted?
This trial has 2 study locations across Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06125743's enrollment target sits among peer trials
204 500th of 2000 higher than 1,498 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI